[go: up one dir, main page]

WO2007047998A3 - Mutations et polymorphismes du gène de l'hdac2 - Google Patents

Mutations et polymorphismes du gène de l'hdac2 Download PDF

Info

Publication number
WO2007047998A3
WO2007047998A3 PCT/US2006/041168 US2006041168W WO2007047998A3 WO 2007047998 A3 WO2007047998 A3 WO 2007047998A3 US 2006041168 W US2006041168 W US 2006041168W WO 2007047998 A3 WO2007047998 A3 WO 2007047998A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdac2
mutations
mutant
polymorphisms
various aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/041168
Other languages
English (en)
Other versions
WO2007047998A2 (fr
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2007047998A2 publication Critical patent/WO2007047998A2/fr
Publication of WO2007047998A3 publication Critical patent/WO2007047998A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne d'une façon générale le test analytique in vitro d'échantillons de tissus et, plus particulièrement, des aspects de mutations et polymorphismes génétiques du gène de l'HDAC2. L'invention concerne de nouvelles mutations et de nouveaux polymorphismes d'un seul nucléotide (SNP) du gène de l'HDAC2, utiles dans le diagnostic et le traitement de patients qui en ont besoin. Par conséquent, les différents aspects de la présente invention concernent des polynucléotides codant pour les mutations de l'HDAC2 de l'invention, des vecteurs d'expression codant pour les polypeptides mutants de l'HDAC2 de l'invention et des organismes qui expriment des polynucléotides mutants et polymorphes du gène de l'HDAC2 et/ou des polypeptides mutants/polymorphes de l'HDAC2 de l'invention. Les différents aspects de la présente invention concernent en outre des procédés et kits de diagnostic/théranostic qui utilisent les mutations et polymorphismes du gène de l'HDAC2 de l'invention pour identifier des individus ayant une prédisposition à une maladie ou pour classifier les individus en ce qui concerne la réponse à un médicament, les effets secondaires d'un médicament ou le dosage optimal d'un médicament.
PCT/US2006/041168 2005-10-21 2006-10-19 Mutations et polymorphismes du gène de l'hdac2 Ceased WO2007047998A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72882205P 2005-10-21 2005-10-21
US60/728,822 2005-10-21

Publications (2)

Publication Number Publication Date
WO2007047998A2 WO2007047998A2 (fr) 2007-04-26
WO2007047998A3 true WO2007047998A3 (fr) 2008-03-13

Family

ID=37890299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041168 Ceased WO2007047998A2 (fr) 2005-10-21 2006-10-19 Mutations et polymorphismes du gène de l'hdac2

Country Status (1)

Country Link
WO (1) WO2007047998A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997002A (zh) * 2017-07-13 2020-04-10 麻省理工学院 靶向hdac2-sp3复合体以增强突触功能
WO2019055236A1 (fr) 2017-09-18 2019-03-21 Massachusetts Institute Of Technology Peptides inhibiteurs de kinase 5 dépendante de la cycline (cdk5)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (fr) * 2000-09-01 2002-03-21 Novartis Ag Inhibiteurs de desacetylase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (fr) * 2000-09-01 2002-03-21 Novartis Ag Inhibiteurs de desacetylase

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACHARYA MILIN R ET AL: "Rational development of histone deacetylase inhibitors as anticancer agents: A review", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 68, no. 4, 2005, pages 917 - 932, XP002423309, ISSN: 0026-895X *
GEORGE ET AL: "COMBINATION OF THE HISTONE DEACETYLASE INHIBITOR LBH589 AND THE HSP90 INHIBITOR 17-AAG IS HIGHLY ACTIVE AGAINST HUMAN CML-BC CELLS AND AML CELLS WITH ACTIVATING MUTATION OF FLT-3", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 105, no. 4, 28 October 2004 (2004-10-28), pages 1768 - 1776, XP008075090, ISSN: 0006-4971 *
MAI ANTONELLO ET AL: "HISTONE DEACETYLATION IN EPIGENETICS: AN ATTRACTIVE TARGET FOR ANTICANCER THERAPY", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 25, no. 3, May 2005 (2005-05-01), pages 261 - 309, XP009075075, ISSN: 0198-6325 *
MONNERET C: "Histone deacetylase inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 40, no. 1, January 2005 (2005-01-01), pages 1 - 13, XP004708959, ISSN: 0223-5234 *
PARK J M ET AL: "no association between polymorphisms in the histone deacetylase genes and the risk of lung cancer", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH,, US, vol. 14, no. 7, July 2005 (2005-07-01), pages 1841 - 1843, XP002424811, ISSN: 1055-9965 *
REMISZEWSKI S W ET AL: "N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2E)-N-hydroxy-3-[4-[[2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]me thyl]phenyl]-2-propenamide (NVP-LAQ824)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 46, 2003, pages 4609 - 4624, XP002414496, ISSN: 0022-2623 *
ROPERO S ET AL: "A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition", NATURE GENETICS, NEW YORK, NY, US, vol. 38, no. 5, 16 April 2006 (2006-04-16), pages 566 - 569, XP002401873, ISSN: 1061-4036 *
WADE P A: "Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin.", HUMAN MOLECULAR GENETICS APR 2001, vol. 10, no. 7, April 2001 (2001-04-01), pages 693 - 698, XP002463805, ISSN: 0964-6906 *

Also Published As

Publication number Publication date
WO2007047998A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007016532A3 (fr) Mutations et polymorphismes de hdac4
WO2009132058A3 (fr) Niveaux d’expression de la protéine bcma sur les lymphocytes b et utilisation dans de méthodes diagnostiques
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2005033652A3 (fr) Procedes pour comparer des debits relatifs d'au moins deux molecules biologiques in vivo dans un protocole simple
WO2006127861A3 (fr) Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides
WO2002022879A3 (fr) Detection de l'instabilite des microsatellites et utilisation de celle-ci dans le diagnostic de tumeurs
WO2005040396A3 (fr) Systeme d'essai qrt-pcr pour le profilage d'expression genetique
EP2517727A3 (fr) Biomarqueurs pour la sclérose en plaques et procédés d'utilisation de ceux-ci
WO2009065132A8 (fr) Prédiction et diagnostic de patients atteints d'une maladie auto-immune
EP2293074A3 (fr) Procédé pour le diagnostic de maladies neuro-dégénératives
WO2006130527A3 (fr) Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes
WO2007022041A3 (fr) Mutations et polymorphismes de l'hdac3
WO2006110478A3 (fr) Mutations et polymorphismes du recepteur du facteur de croissance epidermique
EP2287340A3 (fr) Procédé de diagnostic et traitement d'une maladie mentale
WO2007030455A3 (fr) Mutations et polymorphismes de hdac10
WO2005024067A3 (fr) Analyse genetique permettant une stratification du risque de cancer
WO2007058992A3 (fr) Mutations et polymorphismes de hdac6
WO2005015155A3 (fr) Methodes de comparaison des debits relatifs d'au moins deux molecules biologiques in vivo au moyen d'un seul protocole
WO2007038073A3 (fr) Mutations et polymorphismes de l’hdac11
WO2007030454A3 (fr) Mutations et polymorphismes de hdac9
WO2007047998A3 (fr) Mutations et polymorphismes du gène de l'hdac2
WO2007109183A3 (fr) Mutations et polymorphismes de la tyrosine kinase 1 liée au fms
WO2006123955A3 (fr) Procedes et compositions d'evaluation des fonctions et troubles pulmonaires
WO2004113574A3 (fr) Methodes de depistage d'une maladie
WO2007002217A3 (fr) Mutations et polymorphismes de bcl-2

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06826408

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06826408

Country of ref document: EP

Kind code of ref document: A2